Evidence map›Paper›PMID 28714882›Full record

ArticleInternational journal of molecular sciences2017

Vitamin D Supplementation Enhances C18(dihydro)ceramide Levels in Type 2 Diabetes Patients.

Alexander Koch, Georgios Grammatikos, Sandra Trautmann, Yannick Schreiber, Dominique Thomas, Franziska Bruns, Josef Pfeilschifter, Klaus Badenhoop, Marissa Penna-Martinez

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Vitamin DNutrients · 2020
    Trial
  4. Review
  5. Article
  6. Review
  7. Article
  8. Interplay between Vitamin D and Sphingolipids in Cardiometabolic Diseases.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alexander KochDepartment of General Pharmacology and Toxicology, Goethe University Hospital, 60590 Frankfurt am Main, Germany. koch@med.uni-frankfurt.de.
Georgios GrammatikosDepartment of General Pharmacology and Toxicology, Goethe University Hospital, 60590 Frankfurt am Main, Germany. georgios.grammatikos@kgu.de.
Sandra TrautmannDepartment of Clinical Pharmacology, Goethe University Hospital, 60590 Frankfurt am Main, Germany. labocha@med.uni-frankfurt.de.
Yannick SchreiberFraunhofer Institute of Molecular Biology and Applied Ecology-Project Group Translational Medicine and Pharmacology (IME-TMP), 60590 Frankfurt am Main, Germany. schreiber@med.uni-frankfurt.de.
Dominique ThomasDepartment of Clinical Pharmacology, Goethe University Hospital, 60590 Frankfurt am Main, Germany. thomas@med.uni-frankfurt.de.
Franziska BrunsDepartment of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, Goethe University Hospital, 60590 Frankfurt am Main, Germany. franziskabruns85@gmail.com.
Josef PfeilschifterDepartment of General Pharmacology and Toxicology, Goethe University Hospital, 60590 Frankfurt am Main, Germany. pfeilschifter@em.uni-frankfurt.de.
Klaus BadenhoopDepartment of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, Goethe University Hospital, 60590 Frankfurt am Main, Germany. badenhoop@em.uni-frankfurt.de.
Marissa Penna-MartinezDepartment of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, Goethe University Hospital, 60590 Frankfurt am Main, Germany. Marissa.Penna-Martinez@kgu.de.
Goethe University Frankfurt · DEInstitute of Molecular Biology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sphingolipids are characterized by a broad range of bioactive properties. Particularly, the development of insulin resistance, a major pathophysiological hallmark of Type 2 Diabetes mellitus (T2D), has been linked to ceramide signaling. Since vitamin D supplementation may slow down T2D progression by improving glucose concentrations and insulin sensitivity, we investigated whether vitamin D supplementation impacts on plasma sphingolipid levels in T2D patients. Thus, plasma samples of 59 patients with non-insulin-requiring T2D from a placebo-controlled, randomized, and double-blind study were retrospectively analyzed. Once per week, patients received either 20 drops of Vigantol oil, corresponding to a daily dose of 1904 IU/d vitamin D (verum:

Indexed as

Dietary SupplementsCeramidesDiabetes Mellitus, Type 2FemaleHumansLysophospholipidsMaleMiddle AgedSphingosineVitamin DCeramidesLysophospholipidsN-stearoylsphinganinesafingolSphingosinesphingosine 1-phosphateVitamin Dceramidedihydroceramidesphingolipid metabolismsphingosine 1-phosphateType 2 Diabetes mellitusvitamin D

Identifiers

PMID28714882
PMCPMC5536020
OpenAlexW2734424058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.